Company Filing History:
Years Active: 2020-2022
Title: Giovanni Sandrone: Innovator in Antitumor Compounds
Introduction
Giovanni Sandrone is a notable inventor based in Novara, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with antitumor activity. With a total of 2 patents to his name, Sandrone's work is paving the way for innovative treatments in cancer therapy.
Latest Patents
One of Sandrone's latest patents is focused on Selective HDAC6 inhibitors. This invention relates to novel benzohydroxamic compounds that exhibit a high selective inhibitory activity against the histone deacetylase 6 (HDAC6) enzyme. Another significant patent involves Benzo-N-hydroxy amide compounds that demonstrate antitumor activity. This invention pertains to new benzo-N-hydroxy amide compounds that show a significant inhibitory effect on the proliferation of tumor cells, specifically targeting cancer stem cells.
Career Highlights
Giovanni Sandrone is currently associated with Italfarmaco Spa, a company known for its commitment to research and development in the pharmaceutical sector. His work at Italfarmaco has allowed him to focus on innovative solutions for cancer treatment, contributing to the advancement of medical science.
Collaborations
Sandrone collaborates with talented professionals in his field, including Barbara Vergani and Gianluca Fossati. These collaborations enhance the research and development efforts at Italfarmaco Spa, fostering an environment of innovation and discovery.
Conclusion
Giovanni Sandrone's contributions to the field of pharmaceuticals, particularly in the development of antitumor compounds, highlight his role as an influential inventor. His patents reflect a commitment to advancing cancer treatment, showcasing the importance of innovation in medicine.